Chlordiazepoxide is the first clinically introduced benzodiazepine, potentiating GABA-A receptor activity to produce anxiolytic, sedative and anticonvulsant effects, used for anxiety and alcohol withdrawal syndrome. Simson Pharma's Chlordiazepoxide reference standard and impurities support compendial and controlled-substance-aligned testing for this historic benzodiazepine.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Chlordiazepoxide Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.